Detecting and Managing Chronic Kidney Disease





Primary Care Education Workshop This module was conceived and developed by PEAK*

Presented By:



Collaborators

*This Education was conceived and developed by the 'Primary Care Education Advisory Committee for KHA' (PEAK)

With special thanks to Prof Robyn Langham, Nephrologist; A/Professor Timothy Mathew, Nephrologist; and review by A/Prof Craig Nelson & Dr Sheena Wilmot





Speaker Disclosure Statement

- Kidney Health Australia Primary Care Workshops are presented by volunteer speakers (Nephrologists, Renal Nurses & other Health Professionals).
- Speaker to add any other disclosures



Learning outcomes

State the major risk factors for developing chronic kidney disease (CKD)

Recognise the importance of early detection and management for individuals at risk for CKD

Define the treatment options to delay progression of kidney disease

Implement a practice-based system, for patient safety, to identify patients at higher risk of CKD for a kidney health check





What is CKD?

Chronic kidney disease is defined as:

Glomerular Filtration Rate (GFR) < 60 mL/min/1.73m² for \geq 3 months with or without evidence of kidney damage.

OR

Evidence of kidney damage (with or without decreased GFR) for ≥3 months:

- albuminuria
- haematuria after exclusion of urological causes
- pathological abnormalities
- anatomical abnormalities



CKD is a major public health problem

- 1 in 10 Australian adults has CKD
- Less than 10% of people with CKD are aware they have the condition
- You can lose up to 90% of your kidney function before experiencing any symptoms
- Major independent risk factor for cardiovascular disease



Common, harmful & treatable





GP role in CKD

Reduce the impact of CKD





Kidney disease in Australia





Australians living with signs of Brisbane CKD

> 12% of population with signs of CKD

8-11% of population with signs of CKD

< 7% of population with signs of CKD

No data available



State of the Nation

Non-Indigenous 9,800 7.9%

Indigenous 12,000 32.4%

т

Australia:

Non-Indigenous 1,712,500 10.0% Indigenous 59,600 17.9%

QLD

Non-Indigenous 345,100 10.2% Indigenous 16,200 18.4%

NSW

Non-Indigenous 586,400 10.6% Indigenous 15,400 14.6%

ACT

Non-Indigenous 20,200 7.3%

VIC Non-Indigenous 425,100 9.8%

TAS Non-Indigenous 43,100 11.3%

Figure 5. Living with signs of CKD – Number of people (proportion of population)⁸



State of the Nation Report 2016, Kidney Health Australia

WA Non-Indigenous 176,900 10.1% Indigenous 10,200 22.8%

SA

Non-Indigenous 106,000 8.4% Indigenous 3,300 17.5%

The future Growth in incidence rate of new treated ESKD and projections to 2020 (AIHW, 2011)

Number per 100,000 population



Note: The alternative projection results (lower dotted line) are derived by holding the average of incidence rates for years 2007–2009 for patients 70 years and over constant in projection years.

Source: Registered cases during 1996-2009 from ANZDATA .



Costs of treating current and new ESKD cases to 2020

- The cost of treating ESKD from 2009 to 2020 is estimated to be around \$12 billion to the Australian government
- Kidney disease contributes approximately 15% of all hospitalisations in Australia



Age and ESKD Relationship between age and treatment for ESKD





Sparke et al, Am J Kidney Dis, 2012



Staging CKD

Combine eGFR stage, albuminuria stage and underlying diagnosis to specify CKD stage e.g. stage 3b CKD with microalbuminuria secondary to diabetic kidney disease

| | | A | Ibuminuria Stag | e | |
|--------------|--------------------------|---|---|---|--|
| GFR Stage | GFR mL/min/1. 73m² | Normal | Microalbuminuria | Macroalbuminuria | ACTION PLANS Below are the Clinical Action Plans for the three stages of Chronic Kidney Disease (measured using GFB and urice ACR) compiled from Kidney Health |
| | | urine ACR mg/mmol Male: < 2.5 Female: < 3.5 | urine ACR mg/mmol Male: 2.5-25 Female: 3.5-35 | urine ACR mg/mmol Male: > 25 Female: > 35 | Australia Guidelines. They are categorised yellow, orange and red indicating the overall risk of progression of CKD and cardiovascular events. |
| 1 | ≥90 | Not CKD unless | | | VELLOW > |
| 2 | 60-89 | or pathological abnormalities present | | | RED > |
| 3a | 45-59 | | | | Chronic Kidney Disease (CKD) |
| 3b | 30-44 | | X | | General Practice Guidarce and chical tips to helo identily, manage and refor patients with CKD in your practice |
| 4 | 15-29 | | | | |
| 5 | <15 or on dialysis | | | | |

Colour-coded Clinical Action Plans in handbook and on CKD-Go! App





Staging CKD

'*CKD management in General Practice*' handbook uses colourcoded action plans indicating the overall <u>risk</u> of

- Progression of CKD
- Cardiovascular events

Chronic Kidney Disease (CKD) Management in General Practice



Guidance and clinical tips to help identify, manage and refer patients with CKD in your practice



3rd Edition 2015 • www.kcatorg.au
Prevent, Detect, Support.





CKD and CVD risk CKD prognosis consortium



N.B.

- As GFR decreases CV mortality increases
- The presence of albumin (micro and macro) increases CV mortality at the 'normal' range of GFR

Note log scale on Y axis for Hazard Ratio

Blue – normal ACR, Green – microalbuminuria, Red - macroalbuminuria



CKD and CVD risk CKD prognosis consortium



N.B.

The risk of CV mortality increases for GFR <60mL/min/1.73m² this is the same across all conditions and all levels of albuminuria

Note log scale on Y axis for Hazard Ratio

Blue – normal ACR, Green – microalbuminuria, Red - macroalbuminuria



Screening for CKD

| Indications for assessment* | Recommended assessments | Frequency | 1 in 3 Australia | |
|--|--|------------------------------|---|--|
| Diabetes Hypertension Established cardiovascular | Urine ACR, eGFR, blood pressure | | n adults is at increased | |
| disease ^{**} Family history of kidney failure | If urine ACR positive repeat twice over 3 months (preferably first morning void) | Every 1-2 years [†] | risk of CKD due to these risk factors | |
| Obesity (BMI ≥30 kg/m ²) Smoker | If eGFR < 60mL/min/1.73m ² repeat within | | | |
| Aboriginal or Torres Strait Islander origin aged ≥ 30 years [‡] | / days | | | |

History of acute kidney injury

See recommendations in booklet

*Whilst being aged 60 years of age or over is considered to be a risk factor for CKD, in the absence of other risk factors it is not necessary to routinely assess these individuals for kidney disease.

**Established cardiovascular disease is defined as a previous diagnosis of coronary heart disease, cerebrovascular disease or peripheral vascular disease.

- † Annually for individuals with diabetes or hypertension.
- ‡ Refer to booklet for more details regarding recommendations for testing in Aboriginal and Torres Strait Islander peoples.
- ¹⁸ Chronic Kidney Disease (CKD) Management in General Practice, 3rd edition. Kidney Health Australia: Melbourne,



2015

Kidney Health Check



An eGFR < 60 mL/min/1.73m2 = increased risk of adverse renal, cardiovascular and other clinical outcomes, <u>IRRESPECTIVE OF AGE</u>

N.B. Dipstick testing is not a sufficient test for CKD screening

Chronic Kidney Disease (CKD) Management in General Practice, 3rd edition. Kidney Health Australia: Kidney Health Melbourne, 2015

What is GFR?

GFR = Glomerular Filtration Rate

- is accepted as the best measure of kidney function
- can be estimated from serum creatinine using prediction equations
- there is no direct way of measuring
- may fall substantially before serum creatinine is outside the normal range

| eGFR | Indicates |
|---|--|
| >90 mL/min/1.73m ² | Normal GFR in healthy adults (declines with age) |
| 60-90 mL/min/1.73m ² | should not be considered abnormal unless there is evidence of kidney damage. |
| Consistently <60 mL/min/1.73m ² | indicates CKD |



Comparing creatinine and eGFR







Age and kidneys Relationship between age and kidney function







Interpreting eGFR results Clinical situations where eGFR results may be misleading

- acute changes in kidney function
- people on dialysis
- exceptional dietary intake (e.g. vegetarian diet, high protein diet, recent consumption of cooked meat, creatinine supplements)
- extremes of body size
- diseases of skeletal muscle, paraplegia or amputees (may overestimate eGFR) or high muscle mass (may underestimate eGFR)
- children under the age of 18 years
- severe liver disease present
- eGFR values above 90mL/min/1.73m²
- drugs interacting with creatinine excretion (e.g. trimethoprim)



eGFR and drug dosing



Where an eGFR (using CKD-EPI) is on hand it is clinically appropriate to use this to assist drug dosing decision making

Recommendation:

- Dose reduction of some drugs is recommended for patients with reduced kidney function
- Both eGFR (mL/min/1.73m²) and estimated CrCl (mL/min) provide an estimate of relative renal drug clearance
- If using eGFR for drug dosing, body size should be considered, in addition to referring to the approved Product Information
- For drugs with a narrow therapeutic index, therapeutic drug monitoring or a valid marker of drug effect should be used to individualise dosing



Urine testing recommendations

Urine testing for proteinuria Urine Albumin/ Creatinine ratio (ACR) recommended for everyone

Clinical tip

The preferred method for assessment of albuminuria in both diabetes and non-diabetes is urinary ACR measurement in a first void spot specimen

Where a first void specimen is not possible or practical, a random spot urine specimen for urine ACR is acceptable



Urine tests Albumin / Creatinine Ratio (ACR)

- Association between albuminuria and progressive kidney disease in population studies
- Severity of albuminuria is predictive of outcome
- Therapeutic intervention can delay progression of disease and is most effective where there is significant albuminuria
- Microalbuminuria is predictive of progressive renal disease
- Urine ACR accurately predicts renal and cardiovascular risks in population studies and reduction in urine ACR predicts renoprotective benefit in intervention trials



Urine tests Albumin / Creatinine Ratio (ACR)



- An initial ACR test should be repeated on a first void sample if the results are positive for CKD
- Initial ACR testing can be done utilising point of care testing (Siemens machine or similar). A positive result is best confirmed by the pathology laboratory.
- Albuminuria is present if at least 2 out of 3 ACR tests are positive (including initial test)
- CKD is present if albuminuria persists for at least 3 months
- Dipsticks for protein in the urine are now no longer recommended for this purpose as their sensitivity and specificity is not optimal



Urine ACR Approximate equivalents between urine ACR & other measures of albumin & protein

| | Urine ACR (mg/mmol) | 24h urine albumin (mg/day) | Urine PCR (mg/mmol) | 24 h urine protein (mg/day) |
|------------------|------------------------------------|----------------------------------|--------------------------------|-----------------------------------|
| Microalbuminuria | Male: 2.5-25 Female: 3.5- 35 | 30-300 | Male: 4-40 Female: 6- 60 | 50-500 |
| Macroalbuminuria | Male: >25 Female: >35 | >300 | Male: >40 Female: >60 | >500 |



Target blood pressure in adults



| People with | Maintain BP consistently BELOW (mmHg) |
|---------------------------|--|
| Albuminuria | <130/80 |
| Diabetes | <130/80 |
| Chronic Kidney Disease | <140/90 |



KHA-Cari guidelines-Primary prevention of chronic kidney disease: Blood pressure target



Case study - Rita

Background

- 63 years old
- Accountant
- History of mild asthma

Rita is a new patient to your practice



Case study - Rita

Past medical history

- Overweight (BMI 31kg/m²)
- Mild intermittent asthma
- Chronic low back pain
- Mild hypertension

Family history

- Maternal grandmother died of a heart attack in her 60's but also had a history of 'kidney problems'
- Mother has type 2 diabetes
- Father has angina and hypertension



Case study - Rita

| | Smoker: | 20-25 cigarettes per day (25 pack-year history) | |
|--|--------------|---|--|
| | Alcohol: | 1-2 glasses of wine3-4 nights per week | |
| | Allergies: | Nil known | |
| | Medications: | Salbutamol 100mcg/dose as needed | |



Case study - Question

Q1: Does Rita have an increased risk of CKD?



Risk factors for kidney disease

- × Diabetes
- ✓ Hypertension
- Established cardiovascular disease
- Family history of kidney failure
- ✓ Obesity, BMI > 30kg/m²
- Smoker
- Aboriginal or Torres Strait Islander origin
- History of acute kidney injury
- ✓ Age over 60 years

Rita has 4 of the risk factors for CKD

> 1 in 3 Australian adults is at increased risk of CKD due to these risk factors

> > 2015



RACGP Guidelines for preventive activities in general practice 8th edition;

Risk factor - diabetes

- Patients who have diabetes develop CKD in up to 30% of cases.¹
- 1% of adult Australians develop diabetes each year.²

1. Chadban et al. 2009 National Evidence Based Guideline for Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes, Diabetes AustraAlia and the National Health and Medical Research Council (NHMRC), Canberra. 2. Barr et al. 2006, Int. Diab Institute


High blood pressure

High blood pressure can damage the small blood vessels in the kidneys. The damaged vessels cannot filter waste products from the blood the way they should.



Or.....damaged kidneys cause high blood pressure and high blood pressure damages kidneys



Risk factor - family history of kidney failure





Risk factor - obesity

3



Risk factor - smoking





Cidnev

CKD risk factors: Aboriginal or Torres Strait Islander Origin

Number per 100,000 population



Figure 5.4: Prevalence of treated ESKD, by Indigenous status and age, 2013

41

Source: Australian Institute of Health and Welfare 2015.



Cardiovascular disease, diabetes and chronic kidney disease— Australian facts: Aboriginal and Torres Strait Islander people.

AKI & CKD: interconnected syndrome



AKI as an accelerant of CKD

- CKD is a risk for AKI but the problem is bidirectional
- Risk of developing ESRD was enhanced ~4x by superimposition of AKI in CKD patients.
- Severity & frequency of AKI appear to be important predictors of poorer outcomes.



Theoretical range of outcomes after acute kidney injury (AKI).

1. Chawla LS, Amdur RL, Amid S et al. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011: 79: 1361–1369

43 2. 2. Thakar CV, Christianson A, Himmelfarb J et al. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 2011



Screening and assessments

Screening - search* for patients at risk and invite patients for a health check **Health assessment (Items 701, 703, 705, 707, 715)**

| Screen those at risk | Assessments | Health checks |
|---|-------------|--|
| | | |
| Diabetes | 701 | A type 2 diabetes risk evaluation for people aged 40-49 years |
| Hypertension | 703 | (inclusive) with a high risk of developing type 2 diabetes as |
| Established CVD | 705 | determined by the Australian Type 2 Diabetes Risk Assessment |
| Family history of kidney failure | 707 | Tool – once every 3 years to eligible patients |
| Obesity (BMI >30kg/m²) | 715 | A health assessment for people aged |
| Smoker | | risk of developing chronic disease – |
| Aboriginal or Torres Strait Islander origin History of acute kidney injury | | once only to an eligible patient |

For more information visit <u>www.mbsonline.gov.au</u>

*data management tools such as 'PEN CAT' can be useful to find patients



Case study - Question

Q2: What would you do next?



Case study - Rita

You determine that Rita should have a kidney health check every year







Case study - Rita

Rita's Kidney Health Check results

| Creatinine | 118 µmol/L |
|----------------|------------------------------|
| eGFR | 55 mL/min/1.73m ² |
| Urine ACR | 5.7 mg/mmol |
| Blood pressure | 155 / 95 mmHg |





| | | Albuminuria Stage | | |
|--------------|----------------------------|--|---|---|
| GFR Stage | GFR (mL/min/1.73m ²) | Normal (urine ACR mg/mmol) Male: < 2.5 Female: < 3.5 | Microalbuminuria (urine ACR mg/mmol) Male: 2.5-25 Female: 3.5-35 | Macroalbuminuria (urine ACR mg/mmol) Male: > 25 Female: > 35 |
| 1 | ≥90 | Not CKD unless haematuria, structural | | |
| 2 | 60-89 | or pathological abnormalities present | | |
| 3a | 45-59 | | RITA'S RESULTS STAGE HER HERE | |
| 3b | 30-44 | | | |
| 4 | 15-29 | | | |
| 5 | <15 or on dialysis | | | |



Case study - Question

Q3: Do Rita's Kidney Health Check results mean she has Chronic Kidney Disease?

Not yet

To diagnose Rita with CKD, her urine ACR & eGFR needs to be repeated and results must be consistent over 3 months or more.



Case study - Rita

- If the first ACR is a random spot, then repeat tests should ideally be first morning void specimens
- CKD is present if at least 2 out of 3 ACR tests (including the initial test) in the next three months are positive
- When initial eGFR is <60 mL/min/1.73m² consider clinical situations where eGFR results may be unreliable/misleading
- To confirm CKD, the repeat eGFR in 3 months time should also be below 60mL/min/1.73m²



Repeating the urine ACR

Factors other than CKD known to increase urine albumin excretion...

- Urinary Tract Infection
- High dietary protein intake
- Congestive cardiac failure
- Acute febrile illness
- Heavy exercise within 24 hours
- Menstruation or vaginal discharge
- Drugs (especially NSAIDs)



Case study - Question

Rita comes back to see you three months later and you repeat her urine ACR, eGFR and blood pressure...

| Test | 1 st visit | This visit |
|--------------|------------------------------|------------------------------|
| eGFR | 55 mL/min/1.73m ² | 52 mL/min/1.73m ² |
| Urine ACR | 5.7 mg/mmol | 8.4 mg/mmol |
| BP | 155/95 mmHg | 160/95 mmHg |

Q4: What is your next step?



Case study - Rita

You can now diagnose Rita as having CKD stage 3a with microalbuminuria

| | | Albuminuria Stage | | |
|--------------|-----------------------------------|--|---|---|
| GFR Stage | GFR (mL/min/1.73 m²) | Normal (urine ACR mg/mmol) Male: < 2.5 Female: < 3.5 | Microalbuminuria (urine ACR mg/mmol) Male: 2.5-25 Female: 3.5-35 | Macroalbuminuria (urine ACR mg/mmol) Male: > 25 Female: > 35 |
| 1 | ≥90 | Not CKD unless haematuria, structural | | |
| 2 | 60-89 | or pathological abnormalities present | | |
| 3a | 45-59 | | RITA'S RESULTS STAGE HER HERE | |
| 3b | 30-44 | | | |
| 4 | 15-29 | | | |
| 5 | <15 or on dialysis | | | |



Kidney

Health

Australia





d Edition 2015 - www.kest.org.au revent, Detect, Support. KCAT 🧐 🎯 🌧

| | | ି ହି | 🔏 80% 💼 1 | 0:38 |
|--|-----------------------------------|---------------------------------|-------------------------------|------|
| | ACTIO | N PLANS | \$ | |
| Below are the Clinical Action Plans for the three stages of Chronic Kidney Disease (measured using eGFR and urine ACR) compiled from Kidney Health Australia Guidelines. They are categorised yellow, orange and red indicating the overall risk of progression of CKD and cardiovascular events. | | | | |
| | | | | |
| MORE | RISK | | >> LESS RISK | |
| | YEI | LOW | | > |
| | OR | ANGE | | > |
| | R | ED | | > |
| Return to for a p | the calculator ersonalized cla | to enter eGFI assification o | R and urine A of CKD stage | ACR |
| | CKD CA | LCULATOR | | |
| | | | | |

Orange Clinical Action Plan

eGFR 30-59 mL/min/1.73m² with microalbuminuria OR eGFR 30-44 mL/min/1.73m² with normoalbuminuria

Goals of management

- Investigations to determine underlying cause
- Reduce progression of kidney disease
- Assessment of Absolute Cardiovascular Risk
- Avoidance of nephrotoxic medications or volume depletion
- Early detection and management of complications
- Adjustment of medication doses to levels appropriate for kidney function
- Appropriate referral to a nephrologist when indicated





Guidance and clinical tips to help identify, manage and refer patients with CKD in your practice

Prevent, Detect, Sug



Ľ.

Kidney Health

Orange Clinical Action Plan

| nt 755 - www.kct.cog.au nt, Detect, Support. KCAT 🧭 🍥 | Frequency of monitoring | 3 to 6 months |
|--|--------------------------|---|
| তা র ∡া ৪০% ■ 10:38 < ACTION PLANS | Clinical assessment | Blood pressure Weight |
| Below are the Clinical Action Plans for the three stages of Chronic Kidney Disease (measured using eAFR and urine ACR) compiled from Kidney Health Australia Guidelines. They are categorised yellow, orange and red indicating the overall risk of progression of CkD and cardiovascular events. MORE RISK >> VELLOW >> ORANCE > RED > RED > CKD CALCULATOR | Laboratory assessment | Urine ACR eGFR Biochemical profile including urea, creatinine, electrolytes HbA1c (for people with diabetes) Fasting lipids Full blood count Calcium and phosphate Parathyroid hormone (6-12 monthly if eGFR <45 mL/min/1.73m ²) |







| Pr | event, Detect, Support. KCAT 🧐 🤎 👾 |
|----|---|
| | |
| | |
| | • — |
| | ିଟି ନ ୷∎ 10:38 < ACTION PLANS |
| | Below are the Clinical Action Plans for the three stages of Chronic Kidney Disease (measured using GFR and urine ACR) compiled from Kidney Health Australia Guidelines. They are categorised yellow, orange and red indicating the overall risk of progression of CKD and cardiovascular events. |
| | MORE RISK « >>LESS RISK |
| | YELLOW > |
| | ORANGE > |
| | RED > |
| | Return to the calculator to enter eGFR and urine ACR for a personalized classification of CKD stage |
| | CKD CALCULATOR |
| | |

Orange Clinical Action Plan

eGFR 30-59 mL/min/1.73m² with microalbuminuria OR eGFR 30-44 mL/min/1.73m² with normoalbuminuria

It is also important to consider...

- Absolute Cardiovascular Risk Assessment (www.cvdcheck.org.au)
- Lifestyle modification
- Blood pressure reduction
- Lipid lowering treatments
- Glycaemic control



Case study - Question

Q5: As Rita's general practitioner, how do you reduce her risks of cardiovascular disease?



Cardiovascular risk reduction in CKD

- CKD is one of the most potent known risk factors for cardiovascular disease
- It is essential to clinically determine the risk of CKD before using the Australian absolute cardiovascular risk tool (<u>www.cvdcheck.org.au</u>) to accurately calculate cardiovascular risk
- Individuals with CKD have a 2-3 fold greater risk of cardiac death than individuals without CKD
- People with CKD are at least 20 times more likely to die from cardiovascular disease than survive to need dialysis or transplant



CVD risk Australian Absolute Cardiovascular Disease Risk Calculator www.cvdcheck.org.au



- The tool is approved by NH&MRC
- If Rita had moderate to severe CKD defined as eGFR <45 mL/min/1.73m² or macroalbuminuria (ACR >25mg/mmol men; >35mg/mmol women) she would be at the highest CVD risk and in this case the tool should not be applied



CVD risk anyone with...

• eGFR < 45 mL/min/1.73m² or persistent proteinuria

- Diabetes and microalbuminuria
- Diabetes and age > 60 years
- Established cardiovascular disease
- Familial hypercholesterolemia or total cholesterol above 7.5
- Severe hypertension
 - Systolic 180 mmHg or greater
 - Diastolic 110 mmHg or greater

is already at the <u>highest</u> risk of a cardiovascular event,

therefore the calculator should not be used





Blood pressure reduction

- CKD can cause and aggravate hypertension and hypertension can contribute to the progression of CKD
- Reducing blood pressure to below target levels is one of the most important goals of CKD management
- ACE inhibitor or ARB is recommended first line therapy
- Combined therapy of ACE & ARB is not recommended
- Maximal tolerated doses of ACE inhibitor or ARB is recommended
- Hypertension may be difficult to control and multiple (3-4) medications are frequently required

Rita has stage 3a CKD with microalbuminuria so her blood pressure needs to be maintained consistently below 130/80 mmHg



Blood pressure reduction

Clinical tips

- ACE inhibitors and ARBs can cause a reversible reduction in GFR when treatment initiated
- If the reduction is less than 25% and stabilises within two months of starting therapy... *the ACE inhibitor or ARB should be continued*
- If the reduction in GFR exceeds 25% below the baseline value...

the ACE inhibitor or ARB should be ceased and consideration given to referral to a Nephrologist for bilateral renal artery stenosis



Hypertension

Adequate BP management delays the progression of CKD (reduces the GFR drop/year) MAP (mm Hg)



Bakris et al., Am J Kid Disease, 2000

63

Lifestyle modification



Lifestyle approaches are essential in reducing the overall cardiovascular risk - the key elements are:

'SNAP' (smoking, nutrition, alcohol, physical activity)

- Stop smoking
- A low calorie diet to reduce BMI
- A low salt diet
- A reduction in alcohol intake
- Physical activity
- Weight reduction

Lifestyle modification presents an opportunity to engage the patient in self-management



Lifestyle effects on BP

| Modification | Recommendation | |
|--|---|--|
| Weight reduction | BMI 18-24.9 kg/m ² | 4.4mmHg (for 5.1kg weight lost) |
| Dietary sodium restriction | Reduce dietary sodium intake to no more than 2.4g sodium (or 6g salt) | 4-7mmHg (for reduction by 6g in daily salt intake) |
| DASH diet | Fruit, vegies, low saturated and total fat | 5.5-11.4mmHg (5.5 for normotensives 11.4 for hypertensives) |
| Physical activity | Aerobic activity for 30- 60mins/day, 3-5 days/week | 5mmHg |
| Moderate alcohol consumption only | No more than 2 drinks per day (men) or 1 drink per day (women) | 3mmHg (for 67% reduction from baseline of 3-6 drinks per day) |

Tiberio MFrisoli et al Beyond salt; lifestyle modifications and blood pressure: European Heart Journal (2011) 32, 3081–3087 doi:10.1093/eurheartj/ehr379



Self management

Key self management principles include:

- Engaging the patient in decision making and management of their illness
- Allowing the patient to set appropriate and achievable goals
- Using evidence based, planned care
- Improving patient self management support (e.g. enlisting other health professionals and supports, and better linkages with community resources such as seniors centres, self help groups, skills and support programs)
- A team approach to managing care



Lipid lowering & glycaemic control



Lipids

- Rita's lipids should be assessed
- Lipid-lowering treatment should be considered for CVD risk reduction

Glycaemic control

- Rita's glycaemic control should be assessed
- For people with diabetes, blood glucose control significantly reduces the risk of developing CKD, and in those with CKD reduces the rate of progression





Case study - Question

Q6: Should Rita be referred to a nephrologist?



Referral is recommended if:

- eGFR < 30mL/min/1.73m² (stage 4 or 5 of any cause)
- Persistent significant albuminuria (urine ACR ≥ 30mg/mmol)
- A sustained decrease in eGFR of 25% or more OR a sustained decrease in eGFR of 15mL/min/1.73m², per year
- Uncontrolled hypertension with at least three antihypertensive agents



Clinical tip Anyone with rapidly declining eGFR and/or signs of acute nephritis (oliguria, haematuria, acute hypertension and oedema) should be regarded as a medical emergency and referred with out delay

Current blood chemistry and haematology Urine ACR and urine microscopy for red cell morphology and casts Current and historical blood pressure Urinary tract ultrasound Chronic Kidney Disease (CKD) Management in General Practice, 3rd edition. Kidney Health Australia:



Unnecessary referral if:

- eGFR \geq 30 mL/min/1.73m² is stable
- Urine ACR < 30mg/mmol (with no haematuria)
- Controlled blood pressure

The decision to refer or not must always be individualised, and particularly in younger individuals the indications for referral may be less stringent.

Useful tips

- Pay attention to CVD risk reduction
- Consider discussing management issues with a nephrologist in cases where uncertainty regarding referral exists.
- Don't refer to a nephrologist if targets of therapy are achieved
- Spiral CT angiogram for hypertension is not recommended without specialty advice





Orange Clinical Action Plan

eGFR 30-59 mL/min/1.73m² with microalbuminuria OR eGFR 30-44 mL/min/1.73m² with normoalbuminuria

- Follow the 'Orange' clinical action plan (found in 'CKD management in General Practice' 3rd ed)
- Cardiovascular risk reduction
- Blood pressure should be consistently below 130/80 mmHg – use of ACE or ARB as appropriate
- Lifestyle modification
- Avoid nephrotoxic medications
- Adjust dose of other medications to levels appropriate for her kidney function
- No need for Nephrology referral at this stage
- Continue to monitor 3-6 monthly



Treatment targets for people with CKD Clinical factors

| Parameter | Target | Treatment |
|--|--|--|
| Blood pressure | ≤ 140/90 mmHg or ≤ 130/80 mmHg if albuminuria is present (ACR > 2.5 mg/mmol males; >3.5 mg/mmol females) | Lifestyle modification ACE inhibitor or ARB |
| Albuminuria | >50% reduction of baseline value | ACE inhibitor or ARB |
| *Cholesterol | Total < 4.0 mmol/L LDL < 2.0 mmol/L | Dietary advice statins |
| Blood glucose (for people with diabetes) | HbA1c <7.0% / 53 mmol/mol | Lifestyle modification Oral hypoglycaemic Insulin |

*Clinical guidelines now advise all people with CKD, over the age of 50 years to be prescribed a statin regardless of cholesterol level.


Case study - Question

Q7: What difference does a CKD diagnosis make if I already manage my patients well?



CKD diagnosis, management & patient outcomes



The diagnosis of CKD brings with it the need to identify risk reduction measures both for kidney and cardiovascular diseases

- treatment targets and therapy choices may differ with a CKD diagnosis
- early detection and management of CKD complications for better prognosis
- Ensure dosages of all prescribed drugs are appropriate for kidney function and avoid of nephrotoxic medications
- timely referral of CKD patients to a nephrologist



Summary

- CKD is common, harmful and treatable
- Early detection is beneficial
- Systematically identify patients at high risk of CKD (the 8 risk factors)
- Perform a Kidney Health Check (urine ACR, eGFR, blood pressure) for at risk patients
- Maintain blood pressure consistently below the relevant threshold
- Refer to the CKD staging table and clinical action plans in 'CKD Management in General Practice' booklet
- Most CKD patients can be managed in general practice



Resources

CKD management in General Practice

2015 guidelines handbook

Chronic Kidney Disease (CKD) Management in General Practice

Guidance and clinical tips to help identify, manage and refer patients with CKD in your practice Kidney Health

Available at

www.kidney.org.au /healthprofessionals



3rd Edition 2015 • www.kcat.org.au
Prevent, Detect, Support.



Resources

CKD-GO! Phone App

CKD CALCULATOR Enter your details then hit Go! For a customised Action Plan. Female Male 30 Urine ACR (mg/mmol) eGFR GO!

Rated a **'must have' App** by Medical Observer

Available on iTunes and Google Play app stores

All the best bits of the 'CKD Management in General Practice' handbook now in a handy app!



Resources My Kidneys, My Health Handbook & App Free resource for patients newly diagnosed with early stage CKD

<section-header><text><text><text>

App available on iTunes and Google Play app stores

early stage chronic kidney disease My Kidneys My Health Kidn y Healt y Hea DETECT SUPPORT RESOURCES TEAM DICTIONARY ? FAQ

Hardcopy books available to order visit www.kidney.org.au

Resources CKD patient fact sheets

Available along with more kidney health fact sheets at <u>www.kidney.org.au</u>





1

Resources Healthshare fact sheets

Chronic Kidney Disease fact sheets for patients. Available for Medical Director and Best Practice software



Factsheet

Urinary tract infections

How to look after your kidneys

Kidney Health Check up

GP only – Chronic Kidney Disease

All about Chronic Kidney Disease

Looking after yourself with CKD

Kidney stones

Kidney transplant

Peritoneal dialysis

Consent and kidney tests

Kidney health tests

Kidney cysts

Access for dialysis

Kidney cancer

Treating kidney disease

Homes haemodialysis

Haemodialysis

Life with a single kidney

All about GFR





Resources

Kidney Health Information Service

Free call information service for people living with kidney disease and their families





Kidney Community...

KIDNEY COMMUNITY members receive a **monthly newsletter** from KHA allowing you to access:

- Information and invitations to KHA's education and support activities
- Updates on medical research in kidney disease
- Information on advocacy opportunities and government relations issues
- Information on community and corporate events held by Kidney Health Australia

To join the kidney community, email <u>community@kidney.org.au</u>





Questions?

Thankyou for participating in this workshop

Please complete your evaluation form before leaving.

